Molecular pathogenesis and progression of prostate cancer

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 244-258

  Schrecengost, Randy ^a,b   Knudsen, Karen E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ARN 509; BICALUTAMIDE; CD57 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; DOCETAXEL; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZN 4176; GLUTATHIONE TRANSFERASE P1; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HERMES ANTIGEN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; POLYCOMB GROUP PROTEIN; PROTEIN P130; PROTEIN P63; TESTOSTERONE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACETYLATION; ANDROGEN SYNTHESIS; APOPTOSIS; ARTICLE; BASAL CELL; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL DEDIFFERENTIATION; CELL MATURATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL METABOLISM; CONFORMATIONAL TRANSITION; DEVELOPMENTAL GENE; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; DNA SEQUENCE; EMBRYO DEVELOPMENT; EPITHELIUM BASAL CELL; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LIGAND BINDING; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROSECRETORY CELL; NONHUMAN; ONCOGENE MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRECURSOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; RECURRENCE FREE SURVIVAL; RNA SPLICING; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR GROWTH; UBIQUITINATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; GENE AMPLIFICATION; HUMANS; MALE; MUTATION; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84879459053     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.001     Document Type: Article

References (142)

1. B.S. Knudsen, and V. Vasioukhin Mechanisms of prostate cancer initiation and progression Adv Cancer Res 109 2010 1 50
2. Y.N. Niu, and S.J. Xia Stroma-epithelium crosstalk in prostate cancer Asian J Androl 11 2009 28 35
3. S. Josson, Y. Matsuoka, L.W. Chung, H.E. Zhau, and R. Wang Tumor-stroma co-evolution in prostate cancer progression and metastasis Semin Cell Dev Biol 21 2010 26 32
4. R. Bhatia-Gaur Roles for Nkx3.1 in prostate development and cancer Genes Dev 13 1999 966 977
5. C. Abate-Shen, M.M. Shen, and E. Gelmann Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis Differ Res Biol Divers 76 2008 717 727
6. H.F. English, R.J. Santen, and J.T. Isaacs Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement Prostate 11 1987 229 242
7. N.L. Sandford, J.W. Searle, and J.F. Kerr Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation Pathology 16 1984 406 410
8. H. Isbarn Testosterone and prostate cancer: revisiting old paradigms Eur Urol 56 2009 48 56
9. D. Wang, and D.J. Tindall Androgen action during prostate carcinogenesis Methods Mol Biol 776 2011 25 44
10. X. Wang A luminal epithelial stem cell that is a cell of origin for prostate cancer Nature 461 2009 495 500
11. A.S. Goldstein, J. Huang, C. Guo, I.P. Garraway, and O.N. Witte Identification of a cell of origin for human prostate cancer Science 329 2010 568 571
12. N. Choi, B. Zhang, L. Zhang, M. Ittmann, and L. Xin Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation Cancer Cell 21 2012 253 265
13. A.Y. Chuang Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma Am J Surg Pathol 31 2007 1246 1255
14. H. Song Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis Oncogene 28 2009 3307 3319
15. P.D. Anderson Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis J Clin Invest 122 2012 1907 1919
16. M. Stanbrough, I. Leav, P.W. Kwan, G.J. Bubley, and S.P. Balk Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium Proc Natl Acad Sci U S A 98 2001 10823 10828
17. C. Zhu Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate J Biol Chem 286 2011 33478 33488
18. L. Bubendorf Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 1999 803 806
19. K.K. Waltering Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens Cancer Res 69 2009 8141 8149
20. C. Tran Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
21. M.J. Donovan Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease BJU Int 105 2010 462 467
22. M.J. Linja Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 2001 3550 3555
23. C.D. Chen Molecular determinants of resistance to antiandrogen therapy Nature Med 10 2004 33 39
24. J. Holzbeierlein Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am J Pathol 164 2004 217 227
25. S.Y. Hu Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer Asian J Androl 12 2010 336 343
26. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol Metab 21 2010 315 324
27. M.N. Middleman, R.M. Lush, and W.D. Figg The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate Pharmacotherapy 16 1996 376 381
28. Y.B. Wetherill Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status Cancer Res 65 2005 54 65
29. Y.B. Wetherill Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer Mol Cancer Ther 5 2006 3181 3190
30. C.E. Barbieri Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
31. C.S. Grasso The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
32. M.P. Steinkamp Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy Cancer res 69 2009 4434-2
33. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res 68 2008 5469 5477
34. R. Hu Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 2009 16 22
35. Z. Guo A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
36. Z. Guo A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res 69 2009 2305 2313
37. Y. Li AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression Oncogene 31 2012 4759 4767
38. G. Jenster, H.A. van der Korput, J. Trapman, and A.O. Brinkmann Identification of two transcription activation units in the N-terminal domain of the human androgen receptor J Biol Chem 270 1995 7341 7346
39. S.C. Chan, Y. Li, and S.M. Dehm Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal J Biol Chem 287 2012 19736 19749
40. R. Hu Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 2012
41. P.A. Watson Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc Natl Acad Sci U S A 107 2010 16759 16765
42. S. Sun Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
43. E. Hornberg Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PloS One 6 2011 e19059
44. X. Zhang Androgen receptor variants occur frequently in castration resistant prostate cancer metastases PloS One 6 2011 e27970
45. S. Chen, S. Gulla, C. Cai, and S.P. Balk Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation J Biol Chem 287 2012 8571 8583
46. V. Gordon CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation Mol Endocrinol 24 2010 2267 2280
47. L. Gaughan, I.R. Logan, D.E. Neal, and C.N. Robson Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation Nucleic Acids Res 33 2005 13 26
48. D. Gioeli, and B.M. Paschal Post-translational modification of the androgen receptor Mol Cell Endocrinol 352 2012 70 78
49. A.M. Dirac, and R. Bernards The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling Mol Cancer Res 8 2010 844 854
50. K. Xu Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination Cancer Cell 15 2009 270 282
51. P. Chymkowitch, N. Le May, P. Charneau, E. Compe, and J.M. Egly The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process EMBO J 30 2011 468 479
52. S. Kaikkonen SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells Mol Endocrinol 23 2009 292 307
53. Z. Wang Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis Proc Natl Acad Sci U S A 109 2012 3053 3058
54. M. Fu The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity J Biol Chem 279 2004 29436 29449
55. L. Gaughan Regulation of the androgen receptor by SET9-mediated methylation Nucleic Acids Res 39 2011 1266 1279
56. S. Ko Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase Mol Endocrinol 25 2011 433 444
57. P. McCall, L.K. Gemmell, R. Mukherjee, J.M. Bartlett, and J. Edwards Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients Br J Cancer 98 2008 1094 1101
58. M. Manin Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells Biochem J 366 2002 729 736
59. R.B. Montgomery Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res 68 2008 4447 4454
60. E. Efstathiou Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone J Clin Oncol 30 2012 637 643
61. J.S. de Bono Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
62. C. Cai Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
63. J. Richards Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
64. N.J. Clegg ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 2012 1494 1503
65. H.I. Scher Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
66. J.S. de Bono Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor J Clin Oncol 30 2012 4519
67. R.J. Andersen Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 17 2010 535 546
68. Y. Zhang Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer Mol Cancer Ther 10 2011 2309 2319
69. B. Sahu Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer EMBO J 30 2011 3962 3976
70. D. Wang Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA Nature 474 2011 390 394
71. M.A. Augello, T.E. Hickey, and K.E. Knudsen FOXA1: master of steroid receptor function in cancer EMBO J 30 2011 3885 3894
72. M. Ni Targeting androgen receptor in estrogen receptor-negative breast cancer Cancer Cell 20 2011 119 131
73. J.L. Robinson Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 EMBO J 30 2011 3019 3027
74. J. Gerhardt FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer Am J Pathol 180 2012 848 861
75. R.K. Jain, R.J. Mehta, H. Nakshatri, M.T. Idrees, and S.S. Badve High-level expression of forkhead-box protein A1 in metastatic prostate cancer Histopathology 58 2011 766 772
76. M. Gallucci Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma Cancer Lett 237 2006 76 82
77. M. Gallucci Genetic profile identification in clinically localized prostate carcinoma Urol Oncol 27 2009 502 508
78. J. Gil Immortalization of primary human prostate epithelial cells by c-Myc Cancer Res 65 2005 2179 2185
79. K. Williams Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype Prostate 63 2005 369 384
80. T. Iwata MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells PloS One 5 2010 e9427
81. K. Ellwood-Yen Myc-driven murine prostate cancer shares molecular features with human prostate tumors Cancer Cell 4 2003 223 238
82. J. Kim A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53 Oncogene 31 2012 322 332
83. R.B. Jenkins, J. Qian, M.M. Lieber, and D.G. Bostwick Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization Cancer Res 57 1997 524 531
84. N.N. Nupponen, L. Kakkola, P. Koivisto, and T. Visakorpi Genetic alterations in hormone-refractory recurrent prostate carcinomas Am J Pathol 153 1998 141 148
85. C. Kaltz-Wittmer FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy Lab Invest 80 2000 1455 1464
86. B. Gurel Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis Mod Pathol 21 2008 1156 1167
87. D. Hawksworth Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence Prostate Cancer Prostatic Dis 13 2010 311 315
88. Sato K, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst. 1999;91:1574-80.
89. Wolfer A, et al. MYC regulation of a poor-prognosis metastatic cancer cell state. Proc Natl Acad Sci U S A. 2010;107:3698-703.
90. M.A. Rubin, C.A. Maher, and A.M. Chinnaiyan Common gene rearrangements in prostate cancer J Clin Oncol 29 2011 3659 3668
91. R. Mehra Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Cancer Res 68 2008 3584 3590
92. K. Iljin TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming Cancer Res 66 2006 10242 10246
93. N.C. Bastus Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells Cancer Res 70 2010 9544 9548
94. K.D. Mertz Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model Neoplasia 9 2007 200 206
95. S.A. Tomlins Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
96. P.J. Hendriksen Evolution of the androgen receptor pathway during progression of prostate cancer Cancer Res 66 2006 5012 5020
97. C. Lin Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer Cell 139 2009 1069 1083
98. R.S. Mani Induced chromosomal proximity and gene fusions in prostate cancer Science 326 2009 1230
99. Y. Zong ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells Proc Natl Acad Sci U S A 106 2009 12465 12470
100. S.A. Tomlins Role of the TMPRSS2-ERG gene fusion in prostate cancer Neoplasia 10 2008 177 188
101. C. Sun TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation Oncogene 27 2008 5348 5353
102. J. Yu An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression Cancer Cell 17 2010 443 454
103. R. Mehra Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer Mod Pathol 20 2007 538 544
104. J.M. Mosquera Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications Clin Cancer Res 14 2008 3380 3385
105. F. Demichelis TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 2007 4596 4599
106. J.C. Brenner Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 2011 664 678
107. C. Wu Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer J Pathol 227 2012 53 61
108. N. Palanisamy Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma Nat Med 16 2010 793 798
109. K.K. Wong, J.A. Engelman, and L.C. Cantley Targeting the PI3K signaling pathway in cancer Curr Opin Genet Dev 20 2010 87 90
110. R.J. Lonigro Detection of somatic copy number alterations in cancer using targeted exome capture sequencing Neoplasia 13 2011 1019 1025
111. B.S. Taylor Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
112. K. Nacerddine Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer J Clin Inveest 122 2012 1920 1932
113. S. Wang Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation Proc Natl Acad Sci U S A 103 2006 1480 1485
114. S. Wang Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209 221
115. Z. Chen Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 436 2005 725 730
116. M. Narita, and S.W. Lowe Senescence comes of age Nat Med 11 2005 920 922
117. B.S. Carver Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
118. D.J. Mulholland Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 19 2011 792 804
119. D.J. Mulholland Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells Cancer Res 72 2012 1878 1889
120. P. Martin Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition Am J Pathol 179 2011 422 435
121. I. Ahmad HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer Proc Natl Acad Sci U S A 108 2011 16392 16397
122. R.U. Lukacs, S. Memarzadeh, H. Wu, and O.N. Witte Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation Cell Stem Cell 7 2010 682 693
123. M.J. Schiewer mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer Endocr Rel Cancer 19 2012 1 12
124. T. Udayakumar, M.M. Shareef, D.A. Diaz, M.M. Ahmed, and A. Pollack The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy Semin Radiat Oncol 20 2010 258 266
125. A. Sharma The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression J Clin Invest 120 2010 4478 4492
126. J.A. Simon, and R.E. Kingston Mechanisms of polycomb gene silencing: knowns and unknowns Nat Rev Mol Cell Biol 10 2009 697 708
127. R. Margueron, and D. Reinberg The Polycomb complex PRC2 and its mark in life Nature 469 2011 343 349
128. H. Richly, L. Aloia, and L. Di Croce Roles of the Polycomb group proteins in stem cells and cancer Cell Death Dis 2 2011 e204
129. G.J. van Leenders Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features Eur Urol 52 2007 455 463
130. O.R. Saramaki, T.L. Tammela, P.M. Martikainen, R.L. Vessella, and T. Visakorpi The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer Genes Chromosomes Cancer 45 2006 639 645
131. S. Varambally Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Science 322 2008 1695 1699
132. P. Kunderfranco ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer PloS One 5 2010 e10547
133. C.M. Koh Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms Oncotarget 2 2011 669 683
134. Q. Cao Coordinated regulation of polycomb group complexes through microRNAs in cancer Cancer Cell 20 2011 187 199
135. J.C. Zhao Cooperation between Polycomb and androgen receptor during oncogenic transformation Genome Res 22 2012 322 331
136. Q. Cao Repression of E-cadherin by the polycomb group protein EZH2 in cancer Oncogene 27 2008 7274 7284
137. K.R. Chng A transcriptional repressor co-regulatory network governing androgen response in prostate cancers EMBO J 31 2012 2810 2823
138. J. Yu A polycomb repression signature in metastatic prostate cancer predicts cancer outcome Cancer Res 67 2007 10657 10663
139. A. Kumar, J. Shendure, and P.S. Nelson Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements Genome Med 3 2011 23
140. M.F. Berger The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
141. J.D. Kessler A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis Science 335 2012 348 353
142. C. Van Dang, and S.B. McMahon Emerging concepts in the analysis of transcriptional targets of the myc oncoprotein: are the targets targetable? Genes Cancer 1 2010 560 567